{
    "title": "Bristol Myers expands heart drug business with $13 bln deal for MyoKardia",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-8806171/Bristol-Myers-buy-heart-drug-developer-MyoKardia-13-bln.html",
    "date": "2020-10-05",
    "keywords": [
        "bristol",
        "heart",
        "exclusivity",
        "cancer",
        "drug",
        "maddipatla",
        "portfolio",
        "loss",
        "blockbuster",
        "deal",
        "acquisition",
        "year",
        "mavacamten",
        "eliquis",
        "quarter",
        "premium",
        "hcm",
        "co",
        "monday",
        "inc",
        "disease",
        "celgene",
        "oncology",
        "giant",
        "competition",
        "immunotherapy",
        "opdivo",
        "merck",
        "amp",
        "cos",
        "myokardia",
        "value",
        "shy",
        "offer",
        "share",
        "dependence",
        "access",
        "candidate",
        "potential",
        "blood",
        "thinner",
        "market",
        "companys",
        "revlimid",
        "multibillion",
        "dollar",
        "asset",
        "drive",
        "growth",
        "half",
        "decade",
        "risk",
        "indication",
        "analyst",
        "david",
        "condition",
        "cardiomyopathy",
        "application",
        "health",
        "regulator",
        "goal",
        "latestage",
        "study",
        "company",
        "purchase",
        "reporting",
        "manojna",
        "mishra",
        "bengaluru",
        "editing",
        "chakrabarty",
        "sriraj",
        "kalluvila"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}